Structure Therapeutics Inc.

Listed Company

GPCRCIK 0001888886NasdaqLarge AcceleratedPharmaceutical PreparationsE9FY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-141.20M

Total Assets

$1.58B

Equity

$1.52B

Shares Out

212.53M

Op. Cash Flow

$-222.20M

Business

Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company that discovers and develops novel oral small molecule therapeutics targeting G-protein coupled receptors (GPCRs) using structure-based drug discovery and computational chemistry. Its product portfolio centers on oral GPCR modulators, including lead candidates aleniglipron (GLP‑1R), ACCG‑2671 (amylin), ANPA‑0073 (APJ), LTSE‑2578 (LPA1R), and multiple GIP/GCGR discovery-stage programs. The company operates organized programs and wholly owned subsidiaries focused on a metabolic franchise and additional pulmonary and cardiovascular indications, and collaborates with partners such as Schrödinger. It pursues global clinical development, relies on third‑party contract manufacturers across multiple geographies, and plans commercialization through partnerships and standard pharmaceutical distribution channels.

Summary from filing dated 2025-02-27

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Research and development	225	109	70	36
General and administrative	62	49	33	16
Other license income	−100	—	—	—
Gains on sale of non-financial assets	−10	—	—	—
Total operating expenses	177	158	103	53
Loss from operations	−177	−158	−103	−53
Interest and other income, net	36	36	13	1
Loss before provision for income taxes	−141	−122	−89	−51
Provision for income taxes	515,000	310,000	236,000	17,000
Net loss attributable to ordinary shareholders	−141	−123	−90	−51
Net loss per share, basic	−0.8	−0.78	−0.81	−5.51
Net loss per share, diluted	−0.8	−0.78	−0.81	−5.51
Weighted-average ordinary shares used in computing net loss per share attributable to ordinary shareholders, basic	178	158	110	10
Weighted-average ordinary shares used in computing net loss per share attributable to ordinary shareholders, diluted	178	158	110	10
Unrealized gain on investments, net	140,000	393,000	631,000	−110,000
Total other comprehensive income	140,000	393,000	631,000	−110,000
Comprehensive loss	−141	−122	−89	−51

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	800	170	130	26	—
Short-term investments	647	714	338	65	—
Other receivable	100	—	—	—	—
Prepaid expenses and other current assets	24	8	6	2	—
Total current assets	1,570	891	474	93	—
Property and equipment, net	7	3	3	1	—
Operating right-of-use assets	6	4	5	262,000	—
Other non-current assets	717,000	5	45,000	3	—
Total assets	1,584	903	482	98	—
Accounts payable	14	8	5	6	—
Accrued expenses and other current liabilities	47	26	19	7	—
Operating lease liabilities, current portion	3	2	1	260,000	—
Total current liabilities	63	36	25	13	—
Operating lease liabilities, net of current portion	4	2	4	—	—
Other non-current liabilities	647,000	302,000	298,000	—	—
Total liabilities	68	38	29	13	—
Commitments and contingencies (Note 5)	—	—	—	—	—
Undesignated shares - $0.0001 par value; 100,000 shares authorized as of December 31, 2025 and December 31, 2024	—	—	—	—	—
Ordinary shares - $0.0001 par value; 500,000 shares authorized as of December 31, 2025 and December 31, 2024; 212,513 and 171,860 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively	21,000	17,000	14,000	1,000	—
Additional paid-in capital	1,986	1,193	659	2	—
Accumulated other comprehensive income	1	914,000	521,000	−110,000	—
Accumulated deficit	−470	−329	−207	−117	—
Total shareholders' equity	1,516	865	453	−115	−65
Total liabilities and shareholders' equity	1,584	903	482	98	—

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Net loss	−141	−123	−90	−51
Share-based compensation expense	29	19	8	3
Depreciation expense	1	1	300,000	277,000
Accretion of asset retirement obligation	345,000	4,000	21,000	—
Non-cash lease expense	2	2	634,000	347,000
Accretion of net investment discounts	−16	−18	−6	−905,000
Other receivable	−100	—	—	—
Prepaid expenses and other current assets	−16	−1	−4	−305,000
Other non-current assets	4	−5	15,000	−60,000
Accounts payable	5	3	−860,000	2
Accrued expenses and other current liabilities	22	8	12	2
Operating lease liabilities	−2	−2	−315,000	−361,000
Net cash used in operating activities	−222	−117	−79	−46
Purchases of short-term investments	−547	−703	−417	−123
Proceeds from maturities of short-term investments	631	345	151	62
Purchases of property and equipment	−4	−1	−2	−155,000
Proceeds from sale of non-financial asset	10	—	—	—
Net cash provided by (used in) investing activities	90	−359	−268	−62
Proceeds from issuance of pre-funded warrants in 2025 Follow-On Offering, net of underwriting discounts and commissions	94	—	—	—
Proceeds from issuance of ordinary shares in initial public offering, net of underwriting discounts and commissions	—	—	172	—
Proceeds from private placement financing, gross	—	—	300	—
Payments of offering costs	−2	−2	−22	—
Proceeds from issuance of ordinary shares under employee share purchase plan	921,000	632,000	—	—
Proceeds from exercise of share options	5	2	800,000	33,000
Payment of taxes on restricted share units withheld for taxes	−618,000	—	—	—
Net cash provided by financing activities	763	515	452	29
Net change in cash and cash equivalents	630	40	104	−79
Offering costs included in accounts payable and accrued expenses and other current liabilities	442,000	100,000	53,000	—
Operating lease right-of-use assets obtained in exchange for new lease liabilities	5	—	6	—
Purchases of property and equipment in accounts payable and accrued expenses and other current liabilities	894,000	—	48,000	—
Conversion of redeemable convertible preferred shares into ordinary shares upon initial public offering	—	—	200	—
Recognition of asset retirement obligation	—	—	277,000	—
Conversion of non-voting ordinary shares into ordinary shares	—	—	1,000	—
Exchange of ordinary shares to non-voting ordinary shares	—	—	1,000	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro